AFMD vs. ENTA, XBIT, IMMP, ME, DSGN, ACRV, FHTX, ALDX, TSVT, and QURE
Should you be buying Affimed stock or one of its competitors? The main competitors of Affimed include Enanta Pharmaceuticals (ENTA), XBiotech (XBIT), Immutep (IMMP), 23andMe (ME), Design Therapeutics (DSGN), Acrivon Therapeutics (ACRV), Foghorn Therapeutics (FHTX), Aldeyra Therapeutics (ALDX), 2seventy bio (TSVT), and uniQure (QURE). These companies are all part of the "pharmaceutical preparations" industry.
Affimed (NASDAQ:AFMD) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, community ranking, profitability, valuation and dividends.
In the previous week, Affimed had 9 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 11 mentions for Affimed and 2 mentions for Enanta Pharmaceuticals. Enanta Pharmaceuticals' average media sentiment score of 0.93 beat Affimed's score of 0.38 indicating that Enanta Pharmaceuticals is being referred to more favorably in the news media.
Affimed has a beta of 2.05, meaning that its share price is 105% more volatile than the S&P 500. Comparatively, Enanta Pharmaceuticals has a beta of 0.54, meaning that its share price is 46% less volatile than the S&P 500.
30.8% of Affimed shares are owned by institutional investors. Comparatively, 95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. 3.8% of Affimed shares are owned by insiders. Comparatively, 13.6% of Enanta Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Affimed presently has a consensus target price of $45.00, suggesting a potential upside of 934.48%. Enanta Pharmaceuticals has a consensus target price of $19.00, suggesting a potential upside of 52.37%. Given Affimed's stronger consensus rating and higher possible upside, equities research analysts clearly believe Affimed is more favorable than Enanta Pharmaceuticals.
Affimed has higher earnings, but lower revenue than Enanta Pharmaceuticals. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Affimed, indicating that it is currently the more affordable of the two stocks.
Affimed received 120 more outperform votes than Enanta Pharmaceuticals when rated by MarketBeat users. Likewise, 69.92% of users gave Affimed an outperform vote while only 56.47% of users gave Enanta Pharmaceuticals an outperform vote.
Enanta Pharmaceuticals has a net margin of -180.76% compared to Affimed's net margin of -1,280.27%. Enanta Pharmaceuticals' return on equity of -64.85% beat Affimed's return on equity.
Summary
Affimed beats Enanta Pharmaceuticals on 10 of the 18 factors compared between the two stocks.
Get Affimed News Delivered to You Automatically
Sign up to receive the latest news and ratings for AFMD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AFMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
